Revenue segments as reported by the company.

Premiums

Services

Investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefits

Operating costs

Depreciation and amortization

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Humana

Humana Inc. engages in the provision of health insurance services. The firm operates through the following segments: Retail, Group and Specialty and Healthcare Services. The Retail segment consists of products sold on a retail basis to individuals including medical and supplemental plans such as Medicare, and State-based contracts. The Group and Specialty segment contains employer group fully-insured commercial medical products and specialty health insurance benefits marketed to individuals and groups, including dental, vision, military services and other supplemental health & voluntary insurance. The Healthcare Services segment offers services such as pharmacy solutions, provider services, clinical care, predictive modeling and informatics to other Humana businesses, as well as external health plan members, and other employers. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Humana exceeds earnings expectations, focuses on value-based care growth

Humana's strong financial performance and growth in value-based care position the company well for future success. Addressing audit error rates, uncertainties around RADV, and managing costs are key challenges. Opportunities in recruiting, revenue growth, and strategic partnerships offer avenues for further growth.

Humana exceeds Q1 expectations, eyes industry growth amidst challenges

Humana's strong Q1 performance and strategic decisions position it well for growth
Challenges like rate disruptions and Medicaid redeterminations require close monitoring
Opportunities in industry growth, member engagement, and benefit enhancements ahead
Commitment to long-term goals and high-quality service evident in company's outlook

Humana meets Q2 expectations, eyes growth in MA platform

Humana's Q2 performance met expectations with a focus on MA platform growth and disciplined investments.
Challenges include higher utilization in Medicare Advantage and broad-based medical cost trends.
Strategic benefits adjustments and competitive positioning present opportunities for growth and margin expansion.
Expectations for 2024 include maintaining market share, offsetting costs, and achieving strong membership growth.

Humana surpasses Q3 earnings expectations, eyes $37 EPS target

Humana's Q3 performance exceeded expectations, with strong membership growth and strategic initiatives driving future profitability.
While facing challenges in benefit ratios and regulatory changes, Humana remains focused on achieving long-term financial targets.
The company's commitment to operational excellence, membership growth, and pricing actions positions it for sustained success.
Strategic partnerships and risk management efforts showcase Humana's resilience and adaptability in a dynamic healthcare landscape.

Humana faces challenges from rising costs but eyes long-term growth

Humana's Q4 2023 earnings call highlighted challenges from increased medical costs and utilization trends impacting financial performance and outlook.
Despite disappointments in short-term results, the company remains confident in the long-term attractiveness of the Medicare Advantage sector.
Strategic efforts to restore margins, address utilization drivers, and engage with providers reflect a proactive approach to managing industry dynamics.
Balancing profitability with membership growth through benefit adjustments and pricing actions is crucial for Humana's sustainable financial performance.

Humana reports solid Q1 performance, eyes margin recovery in 2025

Humana's Q1 2024 earnings call highlighted a strong start to the year, challenges in the industry for 2025, and a focus on margin recovery and growth opportunities. The company remains confident in its outlook, emphasizing pricing discipline and maintaining a strong value proposition in the market.

Humana surpasses Q2 expectations, addresses cost pressures for growth

Humana's Q2 2024 performance exceeded expectations, driven by strong Medicare business and growth in Medicaid and primary care segments.
Challenges such as medical cost pressures were addressed through mitigation measures, while opportunities lie in strategic initiatives and long-term planning.
The company's focus on value, disciplined cost management, and operational efficiency position it well for sustained growth and value creation.

Humana surpasses Q3 expectations, eyes growth through efficiency and investments

Humana's Q3 performance exceeded expectations, with a focus on balancing earnings and investments. The company is strategically positioned to drive growth through membership expansion and operational efficiency. Challenges include managing costs and understanding market dynamics, with opportunities in improving Stars ratings and expanding senior care services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Humana Inc. engages in the provision of health insurance services. It operates through the Insurance and CenterWell segments. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which refer to as state-based contracts. The CenterWell segment represents payor-agnostic healthcare services offerings, including pharmacy dispensing services, provider services, and home services. The company was founded by David A. Jones, Sr., and Wendell Cherry on August 18, 1961 and is headquartered in Louisville, KY.

AstraZeneca

Elevance Health Inc

Medtronic

Sanofi

Inflation is easing, says a top thinker for BlackRock, the world's largest asset manager. But it's not falling to what Americans have grown used to.

BlackRock's DeSpirito: Brace For Stubborn Inflation

Health insurance and wellness provider Humana (NYSE: HUM) stock has been outperforming the benchmark indexes trading up 4.6% for the year

Humana Proves Vertically Integrated Healthcare Works

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana receives high rankings in the Hispanic Association on corporate responsibility's corporate inclusion index

Humana Receives High Rankings in the Hispanic Association on Corporate Responsibility's Corporate Inclusion Index

Microsoft

Their yields aren't high, but these companies have been aggressively raising their dividend payments in recent years.

2 Underrated Dividend Stocks That Are Aristocrats in the Making

Centene

Molina Healthcare

UnitedHealth Group

A growing customer base and numerous contract wins might drive the Medical-HMO industry. However, high expenses related to technology advancements and a shortage of nurses will dampen margins.

4 HMO Stocks to Watch Despite Escalating Technology Expenses

Humana's revenue rising a significant 66% to $89.4 billion over the last twelve months, compared to $53.8 billion in 2017, 2.

Is There More Upside For Humana Stock?

Eli Lilly

McKesson

Neurocrine Biosciences

Vertex Pharmaceuticals

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market. The post S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market appeared first on Investor's Business Daily.

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

CVS Health

Cano Health

Source: metamorworks / Shutterstock Cano Health (NYSE: CANO ) stock is moving on Friday from reports that Humana (NYSE: HUM ) and CVS (NYSE: CVS ) are considering buying the company. According to insider sources, both companies have expressed interest in buying out CANO and bringing the company into their folds.

CANO Stock Moves as Humana, CVS Consider Acquisition

Humana could be considering buying Cano Health, according to a Wall Street Journal (WSJ) report citing unnamed sources. This comes amid a broader movement of healthcare giants buying out primary-care providers.

Cano Health Courts CVS, Humana as Buyout Suitors

Humana Inc.  HUM, +0.67% and other possible buyers are circling Cano Health Inc. CANO, +32.17% ,  according to people familiar with the situation, as healthcare heavyweights scramble to snap up primary-care providers.

Humana among potential buyers for Cano Health

Humana and CVS Health are among the several companies looking to buy senior-care facility operator Cano Health , according to media reports on Thursday, sending Cano's shares up about 50%.

Humana, CVS among firms looking to buy Cano Health - reports

Humana Inc. and other possible buyers are circling Cano Health Inc., according to people familiar with the situation, as healthcare heavyweights scramble to snap up primary-care providers.

Humana, Other Potential Buyers Circle Cano Health

Apple

AutoZone

Norwegian Cruise Line

Here are four top stocks to buy in the stock market today according to analysts.

Good Stocks To Invest In Now? 4 Blue Chip Stocks To Buy According To Analysts

Humana (HUM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Humana (HUM) Surges 8.4%: Is This an Indication of Further Gains?

Humana (HUM) shaking off the discrete COVID-19 headwind from its guidance is an important milestone for the Medical - HMOs space.

Humana (HUM) Hikes Guidance: Here's Why It's a Good Sign

Source: Keith Homan / Shutterstock.com Humana (NYSE: HUM ) stock is heading higher on Thursday after the health insurance company revised its guidance during its Investor Day event. That revised guidance now has Humana expecting adjusted earnings per share of approximately $25 for the full year of 2022.

Humana (HUM) Stock Pops on Revised Guidance

Shares of Humana Inc. HUM, -2.02% bounced 2.0% in premarket trading Thursday, after closing at a three-month low in the previous session, as the health care services company raised its full-year profit outlook. The company now expects net earnings per share of "approximately $23.08," up from a previous estimate of "approximately $20.30.

Humana stock bounces after profit guidance raised, upbeat long-term outlook provided

LOUISVILLE, Ky.--(BUSINESS WIRE)--As previously disclosed, Humana Inc. (NYSE: HUM) will host a virtual Investor Day today, Thursday, September 15, 2022, at 8:30 a.m. eastern time. The Investor Day will include presentations by senior management focusing on Humana's value creation framework as the company continues to gain operational momentum and advance its strategy for sustainable leadership in the value-based care industry. Adjusted EPS Target for FY 2025 As part of today's virtual Investor

Humana Introduces Mid-Term Adjusted EPS Target of $37 in 2025 and Raises Full Year 2022 Adjusted EPS Financial Guidance to ‘approximately $25' at Investor Day

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) announced today that Brad D. Smith, former Executive Chairman, President and CEO of Intuit Inc., has been elected as a member of the Company's Board of Directors. He currently serves as the President of Marshall University, having assumed the role of leading his Alma Mater in January 2022. Prior to joining Marshall, Smith was Executive Chairman of Intuit from January 2019 until January 2022, following 11 years as Intuit's President and C

Humana Elects Brad D. Smith to Board of Directors

It's not easy to choose between these two healthcare heavyweights. Still, one must come out on top.

Humana vs. UnitedHealth: What's the Better Buy?

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) will host a virtual Investor Update on Thursday, September 15, 2022. The Investor Update will include presentations by company leaders focusing on Humana's strategic direction, operational and financial progress as well as expectations for future performance. Presentations will begin at 8:30 a.m. Eastern. The Investor Update webcast and virtual presentation may be accessed via Humana's Investor Relations page at https://humana.gcs-web.co

Humana to Host Virtual Investor Update on September 15, 2022

Humana (HUM) continues to gain on continued top-line growth resulting from its solid Medicaid and Medicare businesses. A strong cash position enables HUM to undertake growth-related investments.

Factors that Make Humana (HUM) an Attractive Bet Now

Humana (HUM) wraps up rebranding KAH's home health operations to the CenterWell brand. This leads to the clubbing of HUM's three payer-agnostic care services into a common suite.

Humana (HUM) Brings Home Health Unit of KAH Under CenterWell

Humana derives the majority of its revenue from government-sponsored health benefits programs, offering a sustainable, predictable revenue stream matched only by a few. The popularity of Medicare among voters shapes policy debate over healthcare fiscal spending. CMS is unlikely to cut reimbursement rates wherever it impacts service levels.

Humana: Time To Adopt A More Defensive Portfolio Strategy

Here is how Humana (HUM) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

News for Humana Stock (HUM)